medigraphic.com
Academia Mexicana de Neurología, A.C.

2006, Number 4

<< Back Next >>

Rev Mex Neuroci 2006; 7 (4)

TrkB gene: The link in the fight against the neuroblastoma

Díaz RJD , Romo JE, Loera OF

Language: Spanish
References: 22
Page: 350-353
PDF size: 103.56 Kb.


ABSTRACT

Objective: It is important to have a knowledge about the molecular genetics related to the neuro-oncology, since have been acquiring so transcendental results that permit, for example, to show genes implied in the tumorous development, as is the case of the neuroblastoma (gene TrkB), and from here, to leave toward novel methods directed to trials of diagnosis and processing. Development: A cell line has developed that express to the gene TrkB to investigate the system signs, through which the expression of the gene produces quimioresistence, and if the BDNF endogenous would be able to activate the receiver TrkB and to initiate the transduction in cells of neuroblastoma Trkb-transfected, as well as the neutralizator of antibodies ability against the BDNF and inhibiting Trk-Selective for interfere with the autocrine activation. Conclusions: The TrkB is capable of protecting to the cells of the neuroblastoma against a variety of cytotoxic drugs, while the BDNF is capable of mediating the cell rescue, being suggested that the ability of the BDNF to activating the TRKB can be capable of blocking the apoptosis induced.


REFERENCES

  1. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002; 62: 6462-6.

  2. Israel MA, Hay RJ, Park JG, Gazdar A. Atlas of human tumor cell lines. San Diego: Academic Press; 1994,p. 42-78.

  3. Prat R, Galeano I, Conde FJ, Febles P, Cortes S. Cerebral neuroblastomas: diagnosis and treatment. Rev Neurol 2002; 7: 688-90.

  4. Javier G, Prats J, Sánchez de Toledo J. Treatment of neuroblastoma. Med Clin (Barc) 1991; 12: 467-70.

  5. Goldsby RE, Matthay KK. Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 2004; 2:107-22.

  6. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004; 45:1172-88.

  7. Pello-Fonseca JM, Gómez-Díaz ME, Suárez-González JA, Corrales-Canel B, Castaño-González D, Muruamendiaraz-Fernández V. Retroperitoneal ganglioneuroma. Actas Urol Esp 1998; 22: 242-6.

  8. Nakagawara A, Arima M, Azar CG, Scarvarda NJ, Brodeur GM. Inverse relationship between Trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-8.

  9. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 7: 2264-79

  10. Nakagawara A, Liu XG, Ikegaki N, White PS, Yamashiro DJ, Nycum, L M, Biegel JA, Brodeur G M. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTrk2). Genomics 1995: 25: 538-46.

  11. López-Almaráz R, Montesdeoca-Melian A, Rodríguez-Luis J. The role of molecular genetics in childhood cancer. An Pediatr (Barc) 2003; 59: 334-44.

  12. Valent A, Danglot G, Bernheim A. Mapping of the tyrosine kinase receptors TrkA (NTrk1), TrkB (NTrk2) and TrkC (NTrk3) to human chromosomes 1q22, 9q22 and 15q25 by fluorescence in situ hybridization. Europ J Hum Genet 1997; 5: 102-4.

  13. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Letters 2001; 169: 107-14.

  14. Nakawara A, Arima-Nakawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the Trk gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54.

  15. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation and invasiveness of human neuroblastoma cells. Cancer Res 1995; 55: 1798-806.

  16. Middlemas DS, Kihl BK, Zhou J, Zhu X. Brain-derived neurotrophic factor promotes survival and chemo-protection of human neuroblastoma cells. J Biol Chem 1999; 27: 16451-60.

  17. Lindvall O, Kokaia Z, Bengzon J, Elmer E, Kokaia M. Neurotrophins and brain insults. Trends Neurosci 1994; 17: 490-6.

  18. Middlemas DS, Kihl BK, Moody NM. Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. J Neurooncol 1999; 45: 27-36.

  19. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3’-kinasa pathway. Cancer Res 2002; 62: 6756-63.

  20. Evans AE, Kisselbach KD, Liu X, Aggert A, Ikegaki N, Camoratto AM, Dionne C, et al. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Pediatr Oncol 2001; 36: 181-4.

  21. Jennings RW, LaQuaglia MP, Leong K, et al. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg 1993; 28: 1168-74.

  22. Azizkhan RG, Haase GM. Current biologic and therapeutic implications in the surgery of neuroblastoma. Semin Surg Oncol 1993; 6: 493-501.




2020     |     www.medigraphic.com